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ABSTRACT
GII.4 noroviruses (NoVs) are the primary cause of epidemic viral acute gastroenteritis. One primary obstacle to successful NoV
vaccination is the extensive degree of antigenic diversity among strains. The major capsid protein of GII.4 strains is evolving rap-
idly, resulting in the emergence of new strains with altered blockade epitopes. In addition to characterizing these evolving block-
ade epitopes, we have identified monoclonal antibodies (MAbs) that recognize a blockade epitope conserved across time-ordered
GII.4 strains. Uniquely, the blockade potencies of MAbs that recognize the conserved GII.4 blockade epitope were temperature
sensitive, suggesting that particle conformation may regulate functional access to conserved blockade non-surface-exposed
epitopes. To map conformation-regulating motifs, we used bioinformatics tools to predict conserved motifs within the protrud-
ing domain of the capsid and designed mutant VLPs to test the impacts of substitutions in these motifs on antibody cross-GII.4
blockade. Charge substitutions at residues 310, 316, 484, and 493 impacted the blockade potential of cross-GII.4 blockade MAbs
with minimal impact on the blockade of MAbs targeting other, separately evolving blockade epitopes. Specifically, residue 310
modulated antibody blockade temperature sensitivity in the tested strains. These data suggest access to the conserved GII.4
blockade antibody epitope is regulated by particle conformation, temperature, and amino acid residues positioned outside the
antibody binding site. The regulating motif is under limited selective pressure by the host immune response and may pro-
vide a robust target for broadly reactive NoV therapeutics and protective vaccines.
IMPORTANCE
In this study, we explored the factors that govern norovirus (NoV) cross-strain antibody blockade. We found that access to the
conserved GII.4 blockade epitope is regulated by temperature and distal residues outside the antibody binding site. These data
are most consistent with a model of NoV particle conformation plasticity that regulates antibody binding to a distally conserved
blockade epitope. Further, antibody “locking” of the particle into an epitope-accessible conformation prevents ligand binding,
providing a potential target for broadly effective drugs. These observations open lines of inquiry into the mechanisms of human
NoV entry and uncoating, fundamental biological questions that are currently unanswerable for these noncultivatable patho-
gens.
Noroviruses (NoVs) are the primary cause of severe acute viralgastroenteritis (1). In the United States alone, the annual
NoV disease burden is estimated to be $2 billion and 5,000 quali-
ty-adjusted life years (2). Globally, NoV-associated deaths are es-
timated at 200,000 per year (3). Usually, disease severity is modest,
but our awareness of morbidity and mortality rates, particularly
among the young, elderly, and immunocompromised, is increas-
ing (4–14). An effective vaccine would benefit not only these
highly susceptible populations, but also military, child care, health
care, and food industry personnel. The primary obstacles to de-
velopment of an effective NoV vaccine are the large number of
antigenic variants, viral evolution, and an incomplete under-
standing of the components of protective immunity. A monova-
lent NoV vaccine based on Norwalk virus virus-like particles
(VLPs) has been demonstrated to be safe and effective at mitigat-
ing the risk of NoV illness and infection (15, 16). Although this is
an important first step, additional studies that include NoV strains
of more epidemiological relevance are needed to address the fun-
damental immunogenetic questions surrounding NoV suscepti-
bility and protection from infection.
Strains from the GII.4 genotype cause 70 to 80% of norovirus
outbreaks, including four pandemics in the last 15 years. Strain
US95/96 (GII.4.1997) caused the pandemic during the mid-1990s
(17, 18), followed by the Farmington Hills strain (GII.4.2002)
(19), the Hunter strain (GII.4.2004) (20–22), and the Minerva
2006b strain (GII.4.2006) (10, 21, 23). Although the number of
documented outbreaks did not significantly increase, GII.4.2006b
was subsequently replaced by the global circulating strain New
Orleans (GII.4.2009) (1, 24). In 2012, the newly emerged Sydney
strain (GII.4.2012) (25, 26) became the predominant circulating
NoV strain worldwide. This pattern of emergent strain replace-
ment of a circulating strain followed by periods of stasis is indic-
ative of epochal evolution and results in new GII.4 strains with
altered antigenicity and ligand binding profiles (27, 28). Impor-
Received 25 April 2014 Accepted 20 May 2014
Published ahead of print 28 May 2014
Editor: T. S. Dermody
Address correspondence to Ralph S. Baric, rbaric@email.unc.edu.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.01192-14
8826 jvi.asm.org Journal of Virology p. 8826 – 8842 August 2014 Volume 88 Number 16
tantly, of the NoVs studied, epochal evolution appears to be re-
stricted to GII.4 NoV strains over the past 25 years.
Currently, there is no validated cell culture model for human
norovirus cultivation. As members of the family Caliciviridae,
NoVs contain positive-sense, single-stranded RNA genomes of
about 7.5 kb. Currently, there are five identified genogroups. Al-
most all human NoV infections are caused by strains from geno-
group I (GI) and GII. Each of these genogroups is further subdi-
vided into 9 and 21 different genotypes, respectively, based
primarily on the amino acid sequence of the major capsid protein
encoded by open reading frame 2 (ORF2) (29). When ORF2 is
expressed in vitro, an abundance of the major capsid protein is
produced (30). Monomers of the major capsid protein first form
dimers; then, 90 dimers self-assemble into icosahedral VLPs that
are morphologically and antigenically indistinguishable from na-
tive virions (31). The capsid protein itself is divided into three
structural domains. The shell (S) domain forms the core of the
particle, and the protruding (P) domain is divided into two sub-
domains: protruding subdomain 1 (P1; residues 226 to 278 and
406 to 530) forms a stalk that extends away from the central core
supporting P2 (residues 279 to 405) (31). The P2 subdomain is the
most surface-exposed region of the particle and has been shown to
interact with potential neutralizing/blockade antibodies and car-
bohydrate binding ligands, such as synthetic histo-blood group
antigens (HBGAs), human saliva, and pig gastric mucin (PGM)
(28, 32–36). In the GII.4 strains, residues of the P2 subdomain are
under selective pressure by the host immune response; this pres-
sure drives viral evolution, resulting in antigenic drift and escape
from herd immunity (28, 35, 37). The lack of a cell culture system
for NoV propagation prompted us to develop an in vitro surrogate
neutralization assay, or antibody “blockade” assay, that measures
the capacity of an antibody to block binding of a VLP to a carbo-
hydrate ligand (28, 35, 38, 39). Importantly, the blockade assay has
been verified by other groups as a surrogate neutralization assay in
infected chimpanzees (40) and Norwalk virus-challenged people
(15, 41). The surrogate neutralization blockade assay has been
critical in mapping evolving GII.4 blockade antibody epitopes in
strains antigenically too similar to be differentiated by enzyme
immunoassay (EIA) (28, 42).
In addition to antigenic drift, several other viral factors corre-
late with new GII.4 strain emergence, including strain recombina-
tion (43) and polymerase fidelity (44, 45). Unfortunately, the ab-
sence of a standard infection model other than humans limits the
possibility to study these mechanisms of viral immune evasion in
depth. To date, only antigenic drift has been shown to directly
impact the effectiveness of the human immune response to miti-
gate NoV infection. Using anti-GII.4 NoV human monoclonal
antibodies (MAbs), we have mapped evolving GII.4 blockade
epitopes (46, 47). Changes in these epitopes correlate not only
with the emergence of new strains, but also with loss of antibody
blockade activity, providing direct evidence that new GII.4 strains
are serial human herd immunity escape variants. Many groups
have used bioinformatics tools to predict potential GII.4 antibody
epitopes (20, 27, 28, 48, 49). By coupling a large panel of anti-NoV
MAbs with molecular genetic approaches, we have validated three
evolving GII.4 blockade epitopes. Epitope A (residues 294, 296 to
298, 368, and 372) is highly variable and changes with each new
GII.4 strain emergence (35, 36, 46, 47). Epitope D (residues 393 to
395) is an evolving blockade epitope that also modulates HBGA
binding of GII.4 strains, providing mechanistic support for the
observed correlation between epitope escape from herd immunity
and altered HBGA binding (28, 47, 49). Epitope E (residues 407,
412, and 413) is a confirmed GII.4.2002 Farmington Hills-specific
blockade epitope (36).
We have also described a GII.4-conserved, conformation-de-
pendent blockade epitope recognized by human MAb NVB 71.4
(47). Although this epitope is conserved across GII.4 strains that
circulated between 1987 and 2012, NVB 71.4 does not have equiv-
alent blockade capacities for all GII.4 VLPs, suggesting the anti-
body binds to a complex epitope comprised of both conserved and
variable residues. NVB 71.4 has diagnostic and therapeutic poten-
tial, and mapping of the epitope recognized by human MAb NVB
71.4 may provide a target for widely protective NoV drugs or
vaccine design.
In this study, we demonstrate that the antibody NVB 71.4
cross-blockade and access to the conserved GII.4 blockade epitope
are regulated by particle conformation, temperature, and amino
acid residues positioned outside the antibody binding site. Strat-
egies to control particle conformation changes will inform NoV
immunogen presentation in VLP-based vaccines and therapeu-
tics.
MATERIALS AND METHODS
Virus-like particles. Synthetically derived (Bio Basic Inc., Amherst, NY)
epitope-engineered or outbreak strain ORF2 genes were inserted directly
into the Venezuelan equine encephalomyelitis (VEE) replicon vector for
the production of virus replicon particles (VRPs), as described previously
(35, 42). Bac-GII.4.2009 (New Orleans) VLPs were the kind gift of Jan
Vinje, Centers for Disease Control and Prevention, Atlanta, GA, and were
produced by expression in the baculovirus system and purified with a
cesium chloride gradient. Uranyl acetate-stained VLPs were visualized by
transmission electron microscopy (TEM). Of note, sequences used to pro-
duce VLPs were identified from stool samples from multiple infected
individuals. Although irregular particles are occasionally seen in all VLP
preparations regardless of the vector expression platform (28, 50), ORF2
proteins that self-assemble into plentiful 40-nm spherical particles that
retain robust binding to conformation-dependent monoclonal anti-
bodies and carbohydrate ligands were considered validated for further
studies.
Monoclonal antibodies. The characteristics of the antibodies used in
this study have been previously published, except those of GII.4.2002.G5.
Details are provided in reference 47 for the human MAbs and in references
35 and 51 for the mouse epitope A MAbs. NVB 71.4 is a broad GII.4
blockade human MAb isolated from a healthy blood donor. GII.4.2002.G5 is
a mouse MAb generated by hyperimmunization with GII.4.2002 VLPs, as
described previously (36). This antibody is now commercially available
from Maine Biotech (MAB227P). Fabs were obtained by papain cleavage
using papain immobilized on beaded agarose resin (30 IU/mg; Pierce),
followed by HiTrap protein A (GE Healthcare) and size exclusion chro-
matography (Superdex 200; GE Healthcare).
BOB assay. For experiments using human polyclonal serum, human
MAbs were purified on protein A or G columns (GE Healthcare) and
biotinylated using the EZ-link NHS-PEO solid-phase biotinylation kit
(Pierce). The competition between polyclonal serum antibodies and bio-
tinylated human MAbs for binding to immobilized VLPs (1 g/ml) was
measured by EIA. Briefly, plasma samples were added to GII.4.1997- or
GII.4.2006-coated plates at different dilutions. After 1 h, biotinylated hu-
man MAb was added at a concentration corresponding to 80% of the
maximal optical-density (OD) level, and the mixture was incubated at
room temperature (RT) for 1 h. The plates were then washed with phos-
phate-buffered saline (PBS)-0.05% Tween 20, and bound biotinylated
human MAb was detected using alkaline phosphatase (AP)-labeled
streptavidin (Jackson ImmunoResearch). The percentage of inhibition
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was tested in duplicate and calculated as follows: {1  [(OD sample  OD
negative control)/(OD positive control  OD negative control)]}  100.
The reciprocal plasma dilution that blocks 80% of binding (BD80) was
calculated by interpolation of curves fitted with a 4-parameter nonlinear
regression. For screening donor plasma samples and human MAb block-
ing of binding of mouse MAbs, the binding titers to respective coated
VLPs were determined by EIA by measuring the dilution required to
achieve 50% maximal binding (50% effective concentration [EC50]), as
previously described (47). EIA plates were coated at 0.25 g/ml VLPs for
human MAb blocking of binding (BOB) of mouse MAb assays.
Predicting epitopes. Guided by the empirical data observed for NVB
71.4, which indicated a conserved GII.4 epitope was present, we reasoned
that differential binding noted between GII and GII.4 strains could be
used to refine the search for a conserved region of the GII.4 capsid se-
quence. Representative capsid amino acid sequences of GII strains and
GII.4 strains (28) from 1974 to 2012 were aligned using ClustalX version
2 (52), and the amino acid residues that were conserved among all GII
capsid sequences and all GII.4 capsid sequences were mapped onto the
GII.4.2004 (Protein Data Bank [PDB] accession no. 3SJP) (53) crystal
structure to identify areas that were conserved among all GII and all GII.4
capsid proteins. The original analysis was performed using the crystal
structure for GII.4.1997, as the distances in the structure used for making
the epitope prediction are more reliable than those in a homology model.
The ERK and EHNQ motifs were identified as regions that were conserved
among GII noroviruses and highly conserved among GII.4 viruses. E316,
R484, and K493 (ERK) and E488, H501, N522, and Q523 (EHNQ) were
identified as conserved residues in these regions that carried a charge and
had exposed side chains that protruded. These sites were targeted for
mutagenesis using the rationale that preserving the charges of the residues
would preserve the structural components necessary for VLP formation.
Of note, epitope location predictions were based on VLP structures, not
native virion structures.
VLP-carbohydrate ligand binding assay. EIA plates were coated with
10 g/ml PGM for 4 h and blocked overnight at 4°C in 5% dry milk in
PBS-0.05% Tween 20 before the addition of increasing concentrations of
VLPs. Bound VLPs were detected with a rabbit anti-GII.4 norovirus poly-
clonal serum made by hyperimmunization with a cocktail of GII.4.1987,
GII.4.2002, GII.4.2006, and GII.4.2009 VLPs, followed by anti-rabbit IgG-
horseradish peroxidase (HRP) (GE Healthcare), and the color was devel-
oped with 1-Step Ultra TMB ELISA HRP substrate solution (Thermo-
Fisher). Each step was followed by washing with PBS-0.05% Tween 20,
and all reagents were diluted in 5% dry milk in PBS-0.05% Tween 20, pH
6.9. VLP binding to PGM is stable between pH 6.3 and 8.1, in agreement
with previously published results (54). All incubations were done at room
temperature. PGM at 10 g/ml is a saturating concentration and cannot
distinguish carbohydrate affinities between VLPs, but it does give the
maximum binding potential of the entire panel of GII.4 VLPs. Half-max-
imal binding (EC50) values were calculated using sigmoidal dose-response
analysis of nonlinear data in GraphPad Prism 6. The percentage of max-
imum binding was compared to the mean optical density at 450 nm
(OD450) of 12 g/ml VLPs.
VLP-carbohydrate ligand binding antibody blockade assay. For
blockade assays, PGM-coated plates were prepared as described above.
VLPs (0.25 g/ml) were pretreated with decreasing concentrations of test
MAb for 1 h before being added to the carbohydrate ligand-coated plates
for 1 h. Wash steps and detection of bound VLPs were as described above.
The percent control binding was defined as the binding level in the pres-
ence of antibody pretreatment compared to the binding level in the ab-
sence of antibody pretreatment multiplied by 100. Antibody-VLP and
VLP-PGM incubations were done at room temperature or 37°C as indi-
cated. All other incubations were done at room temperature. The block-
ade data were fitted using sigmoidal dose-response analysis of nonlinear
data in GraphPad Prism 6. EC50s were calculated for antibodies that dem-
onstrated blockade of at least 50% at the dilution series tested. Monoclo-
nal antibodies that did not block 50% of binding at the highest dilution
tested were assigned an EC50 of 2 times the assay upper limit of detection
for statistical comparison. EC50s between VLPs were compared using one-
way analysis of variance (ANOVA) with the Dunnett posttest when at least
three values were compared or Student’s t test when only two values were
compared. A difference was considered significant if the P value was
0.05. Of note, VLP concentrations in blockade assays are in the low
nanomolar range and therefore cannot discriminate between antibodies
with subnanomolar affinities. Antibody-VLP interactions were validated
for compliance with the law of mass action by performing blockade assays
of GII.4.1997 and GII.4.2006 at 0.25, 0.5, 1, and 2 g/ml VLPs. EC50s for
antibody blockade varied less than 2-fold (1 dilution) between any com-
bination of VLP concentrations tested, indicating that under the test con-
ditions, antibody is in excess of the VLPs and the tenets of the law of mass
action are met for antibody-VLP binding (data not shown). Blockade
assays using human type A or B saliva as the source of carbohydrate ligand
were performed as described previously (55) with 0.5 g/ml VLPs at room
temperature or 37°C.
FIG 1 Antibodies to conserved NoV epitopes are rare in human plasma. The ability of human serum samples (n  100) to block binding of human MAbs was
evaluated using a BOB assay. Shown are the BD80 values of a conserved GII nonblockade epitope antibody (NVB 61.3) and a conserved GII.4 blockade epitope
antibody (NVB 71.4) to GII.4.1997 (A) and GII.4.2006 (B) VLPs. Each symbol represents a different individual. BD80 values of 40 were scored as negative. Total
serum IgG binding to GII.4.1997 and GII.4.2006 was determined by EIA. Reciprocal EC50s are shown on the right. Œ, sera competing for binding of NVB 61.3;
, sera competing for binding of NVB 71.4; *, donor sources of NVB 61.3 and NVB 71.4.
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Antibody relative affinity measurements. Antibody Kd measure-
ments were done as previously described (56) at room temperature and at
37°C. Serial dilutions were tested in duplicate in at least two independent
experiments for each temperature. Briefly, EIA plates were coated with
0.25 g/ml VLPs in PBS, blocked, and incubated with serial dilutions of
test antibody. Bound antibody was detected by anti-human IgG-HRP,
and color was developed as described above. Kd values were calculated
using the one-site specific-binding equation in GraphPad Prism 6. The Kd
values were validated by repeating the above-described assay at a range of
VLP concentrations.
VLP protein A-gold staining. VLPs were incubated with 5 g/ml hu-
man MAb at 37°C, followed by 1/100 dilution of protein A conjugated to
10-nm gold particles at room temperature; adsorbed onto prepared grids;
stained with 2% uranyl acetate; and visualized by TEM. Staining specific-
ity was validated by counting 50 fields of the negative-control (VLP minus
human IgG plus protein A-gold). Only one gold particle was observed
near a VLP in the 50 negative-control fields.
RESULTS
Antibodies to conserved NoV epitopes are rarely detected in hu-
man serum samples. To estimate the fraction of antibodies spe-
cific for conserved GII.4 epitopes in the overall serum antibody
response, 100 serum samples collected from healthy individuals
were assayed for the ability to block binding of human MAbs NVB
61.3 and NVB 71.4 in a BOB assay (57, 58). Both human MAbs
recognize a broad panel of antigenically diverse, epidemiologically
significant GII.4 NoV strain VLPs by EIA, but only NVB 71.4
blocks VLP-ligand interactions (47). When tested against
GII.4.1997 (Fig. 1A) or GII.4 2006 (Fig. 1B), three sera were able to
compete with NVB 61.3 binding while the remaining sera did not
show significant inhibition, in spite of variable binding to tested
VLPs (Fig. 1A and B, right columns). Eighteen serum samples
competed with NVB 71.4 binding to GII.4.1997, and six sera could
FIG 2 Access of NVB 71.4 to the conserved GII.4 blockade epitope is temperature dependent. NVB 71.4 was assayed for the ability to block the interaction of a
panel of time-ordered GII.4 VLPs with carbohydrate ligand. Sigmoidal curves were fitted to the mean percent control binding (the percentage of VLPs bound to
ligand in the presence of antibody pretreatment compared to the number of VLPs bound in the absence of antibody pretreatment) at room temperature (A) and
at 37°C (B), and the mean EC50 titers for blockade at room temperature (solid circles) and at 37°C (grey circles) were calculated and compared (C). The fold
change (arrow denotes decrease) in the EC50 titer was defined as the mean EC50 at 37°C compared to that at room temperature. *, mean EC50 blockade titer
significantly different between room temperature and 37°C. The dotted line in panel C marks the assay upper limit of detection. The error bars represent the
standard errors of the mean (SEM) on the sigmoidal fit curves (A and B) and 95% confidence intervals on the mean EC50 graph (C).
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compete for binding to GII.4.2006 (Fig. 1). These data indicate
that antibodies to GII.4 conserved epitopes may be rare in human
serum samples even if the binding titers to the tested VLPs are high
for the majority of the sera (EC50s are reported in Fig. 1A and B,
right).
The conserved GII.4 blockade epitope is likely not surface
exposed, and antibody access to the epitope is regulated by par-
ticle conformation. To characterize the epitope recognized by
NVB 71.4, we compared the profiles for NVB 71.4 blockade of a
time-ordered panel of GII.4 VLPs representing circulating GII.4
strains from 1987 through 2012. As shown previously (47), block-
ade curves had relatively shallow slopes (range, 0.68 to 0.92) (Fig.
2A). These data suggest that access of NVB 71.4 to the conserved
blockade epitope may be restricted under the test conditions.
Therefore, we repeated the blockade assay for NVB 71.4 against
the panel of GII.4 VLPs at 37°C to increase the probability of the
VLPs adopting a conformation more favorable for antibody bind-
ing during the incubation time (59). Incubation at 37°C signifi-
cantly increased the blockade capacity of NVB 71.4 for the panel of
GII.4 VLPs (Fig. 2B). Further, the blockade curves demonstrated
steep slopes (range, 1.1 to 2.8), with complete blockade reached at
antibody saturation for each VLP. In agreement with previous
findings (47), NVB 71.4 did not block each GII.4 VLP equivalently
at room temperature and 37°C. Incubation at the higher temper-
ature resulted in significantly less antibody needed for blockade of
GII.4.1987 (21.4-fold less), GII.4.1997 (35.4-fold less), GII.4.2002
(5.0-fold less), GII.4.2006 (10.5-fold less), GII.4.2009 (6.9-fold
less), and GII.4.2012 (9.9-fold less) (Fig. 2C). Incubation at 37°C
did not increase the number of strains blocked by NVB 71.4, as the
higher temperature did not allow blockade of any non-GII.4 VLPs
tested (data not shown), in agreement with previous findings at
room temperature (47). Temperature-dependent NVB 71.4
blockade activity was confirmed with the alternative ligand
sources human type A and type B saliva (data not shown). As
demonstrated for PGM, all of the tested VLPs were blocked at
lower concentrations of NVB 71.4 at 37°C compared to RT. Al-
though the temperature effect was retained across ligand sources,
the degree of temperature effect varied both by GII.4 VLP and
between the three types of ligand, in agreement with previous
reports (28, 47).
In contrast, EC50 titers for blockade of surface epitopes A and D
were only minimally impacted by temperature. GII.4.2006 block-
ade by human MAbs that bind to surface-exposed epitopes A and
D required 1.4- and 1.3-fold less antibody, respectively, for 50%
blockade of binding at 37°C than at room temperature (data not
shown). Although the mean EC50 titers for blockade of epitopes A
and D are significantly different between room temperature and
37°C, the difference between the values reflects less than one
2-fold serial dilution. These data indicate that, unlike epitopes A
and D, the conserved blockade epitope recognized by NVB 71.4
may not be readily accessible on the viral particle at all times,
resulting in regulated antibody access under the tested conditions.
In our screen of over 100 mouse MAbs against GII.4 VLPs, we
identified only one MAb with broad GII.4 blockade activity, and
this cross-blockade was temperature dependent (Fig. 3). In agree-
ment with the findings for NVB 71.4, GII.4.2002.G5 mouse MAb
did not block each GII.4 VLP equivalently at room temperature
and at 37°C. Incubation at the higher temperature resulted in less
antibody being needed for blockade of GII.4.1987 (46-fold less),
GII.4.1997 (8.5-fold less), GII.4.2002 (9.2-fold less), GII.4.2006
(10.2-fold less), GII.4.2009 (3.6-fold less), and GII.4.2012 (3.9-
fold less). Incubation at 37°C did not increase the number of
strains blocked (data not shown). The varied degrees of block-
ade between different GII.4 VLPs suggest that the epitope
GII.4.2002.G5 recognizes is composed of both residues that are
conserved and residues that are variable across the GII.4 panel, as
observed for NVB 71.4 (Fig. 2).
Viruses and virus-like particles are dynamic structures, and the
degree of structural flexibility is temperature sensitive and can be
influenced by host factors (59–61). While this study is the first to
show that VLPs produced from VEE replicons likely adopt differ-
ent conformations, to our knowledge, no studies have demon-
strated that viruses or VLPs assembled in the baculovirus insect
cell system, which functions at 27 to 28°C, are similarly dynamic.
FIG 3 Access of GII.4.2002.G5 to a conserved GII.4 blockade epitope is regulated by temperature. GII.4.2002.G5 was assayed for the ability to block the
interaction of GII.4 VLPs with carbohydrate ligand at room temperature (solid circles) and at 37°C (grey circles). Sigmoidal curves were fitted to the mean percent
control binding (the percentage of VLPs bound to ligand in the presence of antibody pretreatment compared to the number of VLPs bound in the absence of
antibody pretreatment), and the mean EC50 titer for blockade was calculated. The fold change (arrow denotes decrease) in the EC50 titer was defined as the mean
EC50 at 37°C compared to that at room temperature. *, mean EC50 blockade titer significantly different between room temperature and 37°C. Nonblockade VLPs
were assigned an EC50 of 2 times the upper limit of detection for statistical analysis and denoted by a data marker on the graph above the dotted line (the assay
upper limit of detection) for visual comparison. The error bars represent 95% confidence intervals.
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Therefore, we compared GII.4.2009 VLPs produced in the bacu-
lovirus-based insect system (27°C) and the VEE-based mamma-
lian system (37°C) for antibody blockade at room temperature
and at 37°C. Importantly, the primary nucleotide sequences of the
two GII.4.2009 capsid constructs are identical (GenBank acces-
sion no. ADD10375). For both mammalian and insect cell-pro-
duced GII.4.2009 VLPs, blockade of surface epitope A was effi-
cient and not temperature sensitive (1.3-fold less antibody was
needed for 50% blockade) (Fig. 4A). Unexpectedly, NVB 71.4
blockade was also not temperature sensitive (1.3-fold more anti-
body was needed at 37°C) for the insect cell-produced VLPs com-
pared to 6.9-fold less antibody needed at 37°C for the mammalian
cell-produced VLPs. Further, NVB 71.4 blockade of GII.4.2009
VLPs produced in insect cells required 29.3-fold less antibody for
50% blockade at room temperature and 3.2-fold less at 37°C than
GII.4.2009 VLPs produced in mammalian cells (0.1133 and
0.1503 g/ml compared to 3.322 at room temperature and 0.4817
g/ml at 37°C) (Fig. 2 and 4B) (47). GII.4.2002.G5 needed 93-fold
less antibody at room temperature and 19-fold less at 37°C for
50% blockade for GII.4.2009 VLPs produced in insect cells than
for VLPs produced in mammalian cells (0.0843 and 0.1173 g/ml
compared to 7.8 g/ml at room temperature and 2.177 g/ml at
37°C) (Fig. 3 and 4C). This lack of temperature effect on Bac-
GII.4.2009 blockade was maintained when type B saliva was used as
the ligand source and when NVB 71.4 Fab fragments were used for
the blocking antibody (data not shown). These data support other
study findings suggesting that factors outside the capsid sequence can
modify VLP antigenicity in subtle ways and support the hypothesis
that antibody access to the conserved GII.4 blockade epitope is regu-
lated by temperature and likely by particle conformation.
Prediction of a conserved GII.4 motif with epitope-like fea-
tures. Using the crystal structure of the GII.4.2004 P domain
dimer (PDB accession no. 3SJP) (53), conserved and variable
amino acids were mapped onto the P domain dimer surface. A
region that was highly conserved among GII.4 norovirus strains
was identified on the side of the P domain dimer (Fig. 5A and B),
within the P1 subdomain, interior to the exposed surface of the P2
subdomain, and distal to the carbohydrate binding pockets that
correlate with differences in binding to NVB 71.4 (Fig. 5B and C).
This region contained several conserved amino acids in an area
large enough to represent a potential antibody binding site
(1,000 Å2), including charged amino acids at positions E316,
R484, and K493 (post-1997 GII.4 numbering) (Fig. 5C). These
amino acids were named the ERK motif (Fig. 5C). The ERK motif
is highly conserved among GII.4 strains that circulated between
1987 and 2012 and was predicted to be either a binding site for or
a regulator of NVB 71.4 binding. In addition, amino acid position
310 was identified as a site of variation among contemporary GII.4
epidemic strains (2009 and 2012) that was proximal to the highly
conserved region containing the ERK motif (Fig. 5D).
Conservation of the ERK motif and its subsurface P1 location
indicated that changes in these residues could be detrimental to
viral particle structure or stability. Therefore, to evaluate the im-
pact of the ERK motif on antibody blockade activity, we designed
mutant VLPs in the GII.4.2006 backbone that conserved the resi-
due charge but changed the residue side chain length. The
GII.4.2006.ERK clone contains substitutions E316D, R484K, and
K493R (Fig. 6A). For comparison, we designed an additional P1
domain mutant based on a conserved GII antibody epitope re-
cently published (62). GII.4.2006.EHNQ contains mutated resi-
FIG 4 Antibody access to the conserved epitope is not temperature sensitive
on GII.4.2009 VLPs made at lower temperature in insect cells. Epitope A hu-
man MAb (A), NVB 71.4 (B), and GII.4.2002.G5 (C) were assayed for the
ability to block the interaction of GII.4.2009 VLPs produced in insect cells
using a baculovirus expression system and carbohydrate ligand at room tem-
perature (solid circles) and at 37°C (grey circles). Sigmoidal curves were fitted
to the mean percent control binding (the percentage of VLPs bound to ligand
in the presence of antibody pretreatment compared to the number of VLPs
bound in the absence of antibody pretreatment), and the mean EC50 titer for
blockade was calculated. The fold change (arrow denotes increase or decrease)
in the EC50 titer was defined as the mean EC50 at 37°C compared to that at
room temperature. *, mean EC50 blockade titer significantly different between
room temperature and 37°C. The error bars represent 95% confidence inter-
vals.
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dues E488D, H501K, N522Q, and Q523N (post-1997 GII.4 num-
bering) (Fig. 6A). The GII.4.2006.ERK substitutions did not
notably alter the particle structure as measured by electron mi-
croscopy (EM) visualization of 40-nm spherical particles and
ligand binding ability similar to that of GII.4.2006. However, mi-
croscopic visualization of the GII.4.2006.EHNQ mutant revealed
numerous irregular structures but no 40-nm spherical particles.
Corresponding to the lack of particle integrity, this mutant was
unable to bind carbohydrate ligand (Fig. 6B and C). Having failed
VLP manufacturing quality control, no additional studies were
performed with mutant GII.4.2006.EHNQ.
The GII.4 conserved ERK motif impacts NVB 71.4 and
GII.4.2002.G5 blockade capacity with little impact on tempera-
ture sensitivity. As the substitutions made within GII.4.2006.ERK
FIG 5 Predicting a conserved epitope. Shown are chain A (dark blue) and chain B (light blue) of the protruding domain structure. (A) The P1 subdomain is
highly conserved among GII.4 epidemic strains and is hidden from the surface in the context of the VLP superstructure. The carbohydrate binding pocket (pink)
is located in the P2 subdomain, which is exposed on the surface of the VLP. (B) A conserved region was identified on the side of the P domain dimer distal to the
binding pockets with sites of variation (red) that correlated with phenotypic differences among GII.4 VLPs. (C) The ERK motif (rotated 60° counterclockwise on
the x axis compared to panel B) is comprised of three charged amino acids that are found at positions 316, 484, and 493 (red) in the conserved region (circled in
red) that is predicted to interact with NVB 71.4. (D) Variation at position 310 (yellow) is proximal to the conserved region and may regulate binding to this
conserved site.
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retained ligand binding activity, we evaluated the impacts of these
residue changes on the blockade potencies of NVB 71.4,
GII.4.2002.G5, and antibodies to surface-exposed epitopes. ERK
substitutions resulted in minimal increases in blockade ability for
both epitope A and D antibodies (1.3-fold less antibody was
needed for 50% blockade at 37°C than at room temperature for
both human MAbs) (data not shown). However, the ERK motif
substitutions resulted in complete loss of blockade potency of
NVB 71.4 at room temperature. Blockade potency was restored at
37°C (2.519 g/ml), although significantly more antibody (4.1-
fold) was needed for blockade than for GII.4.2006 (Fig. 7A). Sim-
ilarly, GII.4.2002.G5 did not block GII.4.2006.ERK at room tem-
perature but gained limited blockade potency at 37°C (11.43 g/
ml) (Fig. 7B). However, significantly more antibody (3.6-fold)
was needed for blockade of GII.4.2006.ERK than for GII.4.2006
even at the elevated temperature. Further, blockade of GII.4.2006
and GII.4.2006.ERK with NVB 71.4 Fab fragments was more po-
tent (lower EC50) than with NVB 71.4 IgG but similarly tempera-
ture sensitive. Notably, the EC50s were 2.1-fold different at room
temperature (1.758 versus 0.8052) and 1.4-fold different at 37°C
(0.1807 compared to 0.1259), indicating that with the smaller
epitope-binding molecule, the ERK residues do not effect antige-
nicity (Fig. 7C). Further, ERK substitutions negatively impact block-
ade potency for both conserved epitope antibodies but do not negate
the compensatory effect of incubation at higher temperature, indicat-
ing that the ERK residues may affect antibody access to the epitope
instead of the antibody binding strength for the epitope.
Quantitative EIAs (56) further indicated that ERK residue sub-
stitutions do not affect antibody affinities. Based on the differ-
ences in blockade titers, if the ERK substitutions primarily affected
antibody affinity, we would expect a 10-fold change in functional
affinity for NVB 71.4 at room temperature and a 4-fold change at
37°C. However, there is less than a 2-fold difference (one serial
dilution) between the antibody functional affinities (Kd values) of
NVB 71.4, GII.4.2002.G5, and epitope D human MAb for
GII.4.2006 and GII.4.2006.ERK VLPs between room temperature
and 37°C (Table 1), clearly indicating that the ERK motif is not the
antibody binding site.
FIG 6 Characterization of VLPs with substitutions in predicted conserved antibody epitopes. (A) Schematic of constructs. (B and C) Particle integrity was
verified by transmission electron microscope visualization (B) and carbohydrate ligand (PGM type III) binding of VLPs (C). Non-PGM-binding VLPs were
assigned an EC50 of 2 times the upper limit of detection for statistical analysis and denoted by a data marker on the graph above the dotted line (the assay upper
limit of detection) for visual comparison. The error bars represent 95% confidence intervals. Scale bars, 100 nm.
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Residue 310 modulates antibody blockade potency and tem-
perature sensitivity. Dominant GII.4 strains circulating between
1987 and 2006 conserved an asparagine at residue 310. With the
emergence of GII.4.2009, N310 became S310. Subsequently,
GII.4.2012 replaced the serine at 310 with an aspartic acid (Fig.
8B). To investigate the role of residue 310 in GII.4 VLPs, we first
developed mutated VLPs that exchanged the 310 residue between
GII.4.2009 and GII.4.2012 (Fig. 9A). These substitutions did not
notably alter the particle structure as measured by electron mi-
croscopy visualization and ligand binding ability (Fig. 9B and C)
or blockade by epitope A or D human MAbs (data not shown). In
these constructs, the ERK motif was unchanged. For both NVB
71.4 and GII.4.2002.G5, exchange of residue 310 between
GII.4.2009 and GII.4.2012 resulted in an exchange of potency and
temperature sensitivity phenotypes (Fig. 10A and B and data not
shown). GII.4.2009.S310D blockade potency decreased 2- and
4.1-fold and temperature sensitivity increased 10.5- and 12-fold
for NVB 71.4 and GII.4.2002.G5, respectively. Conversely,
GII.4.2012.D310S blockade potency increased 2.7- and 3.2-fold
and temperature sensitivity decreased 4.6- and 3.1-fold for each
antibody. NVB 71.4 Fab had modestly increased potency at room
temperature (1- to 2.8-fold) for the 310 mutant VLPs, and the
blockade was less temperature sensitive (2.4- to 8.0-fold) than the
wild type, indicating that the smaller molecule has better access to
the epitope.
To evaluate the interplay between residue 310 and the ERK
motif, we created VLP GII.4.2009.NERK containing both the
S310D and ERK substitutions (S310D, E316D, R484K, and
K493R) (Fig. 9A). This VLP is called NERK instead of SERK be-
cause of the asparagine found at 310 in the GII.4 VLPs from 1987
to 2006. Interestingly, combining the 310 and ERK residue
changes in the GII.4.2009 backbone resulted in a VLP that was
blocked similarly to GII.4.2009 for NVB 71.4 but required 4.1-fold
more GII.4.2002.G5 for 50% blockade. Of note, for both IgGs and
NVB 71.4 Fab, the NERK substitutions reduced the advantage of
incubating at higher temperature by 50% compared to wild-
type VLP blockade. As there was less than a 2-fold difference in Kd
values for NVB 71.4 or GII.4.2002.G5 binding to GII.4.2009 and
GII.4.2009.NERK at room temperature or 37°C (data not shown),
it is unlikely that NERK forms the antibody epitope; instead, 310
and the ERK residues together form a regulating network. Block-
ade by anti-epitope A and D human MAbs was unaffected by the
FIG 7 ERK motif substitutions decrease NVB 71.4 and GII.4.2002.G5 blockade potential with little impact on blockade temperature sensitivity. NVB 71.4 (A and
D), GII.4.2002.G5 (B and E), and NVB 71.4 Fab (C and F) were assayed for the ability to block carbohydrate ligand interaction of GII.4.2006 VLPs at room
temperature (solid circles) and at 37°C (solid squares) and GII.4.2006.ERK VLPs at room temperature (grey circles) and 37°C (grey squares). Sigmoidal curves
were fitted to the mean percent control binding (the percentage of VLPs bound to ligand in the presence of antibody pretreatment compared to the number of
VLPs bound in the absence of antibody pretreatment), and the mean EC50 titers for blockade were calculated and compared. The fold change (arrow denotes
increase or decrease) in the EC50 titer was defined as the mean EC50 at 37°C compared to that at room temperature. *, mean EC50 blockade titer for
GII.4.2006.ERK significantly different from the mean EC50 blockade titer for GII.4.2006 at the same temperature. Nonblockade VLPs were assigned an EC50 of
2 times the upper limit of detection for statistical analysis and denoted by a data marker on the graph above the dotted line (the assay upper limit of detection)
for visual comparison. The error bars represent the SEM on sigmoidal fit curves (A to C) and 95% confidence intervals on the mean EC50 graphs (D to F).
TABLE 1 Monoclonal antibody functional affinities for GII.4.2006 and
GII.4.2006.ERK at room temperature and 37°C
MAb Temp (°C)
Kd (nM) 	 SEM
GII.4.2006 GII.4.2006.ERK
NVB 71.4 RT 0.48 	 0.09 0.56 	 0.01
37 0.27 	 0.01 0.29 	 0.05
GII.4.2002.G5 RT 1.0 	 0.24 2.0 	 0.29
37 0.57 	 0.05 0.87 	 0.11
Epitope D RT 0.78 	 0.09 0.95 	 0.13
37 0.39 	 0.07 0.41 	 0.05
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310 or NERK residue mutation, indicating that the substitutions
specifically targeted the conserved blockade epitopes and did not
cause global particle disturbances (data not shown). These data
indicate that in multiple GII.4 backbones residue 310 has a subtle
effect on blockade potency at room temperature and a more sig-
nificant effect on the temperature sensitivity of the conserved
blockade epitope. Comparison of the effects of serine versus as-
partic acid at position 310 indicates better access to the epitope
because variation in regulating residues reduces the effect of incu-
bation at higher temperature.
NVB 71.4 VLP-ligand interaction blockade is not explained
by particle disassembly or steric hindrance. To explore the
mechanisms of NVB 71.4 blockade, we stained GII.4.2009 and
GII.4.2009.NERK VLPs with NVB 71.4 and epitope A human
MAbs and protein A gold particles and observed antibody-labeled
VLPs by negative-stain electron microscopy (Fig. 11). Both NVB
71.4 and the epitope A human MAbs labeled intact VLPs, indicat-
ing that the antibody-induced lack of ligand binding was not the
result of antibody-mediated particle disassembly or that NVB 71.4
preferentially binds to disassembled capsid protein. To evaluate if
NVB 71.4 binding to subsurface sites altered the particle surface in
a way that was undetectable by EM but rendered the particle not
amenable to interactions at the surface, antibody blockade-of-
binding competition assays were performed using antibodies to
surface-exposed, conformation-dependent epitope A and subsur-
face, conformation-dependent NVB 71.4 (Fig. 12). When VLP-
coated plates were preincubated with an epitope A human MAb,
binding of a mouse epitope A MAb was reduced. The epitope A
human MAb blocked 50% of the binding of a mouse epitope A
MAb at 0.7325 g/ml for GII.4.1997 and 0.1419 g/ml for
GII.4.2006. Binding of the epitope A human MAb did not affect
binding of the mouse MAb GII.4.2002.G5 for either VLP. Like-
wise, a strain-mismatched epitope A human MAb did not affect
binding of either the mouse epitope A or GII.4.2002.G5 antibody
for either VLP. Conversely, preincubation of the VLP with NVB
71.4 did not affect binding of the mouse epitope A MAbs but
decreased binding of GII.4.2002.G5. NVB 71.4 human MAb
blocked 50% of the binding of mouse GII.4.2002.G5 at 0.0982
g/ml for GII.4.1997 and 0.1913 g/ml for GII.4.2006. Com-
bined, these data indicate that VLPs bound by NVB 71.4 retain
conformation and spatial flexibility for interaction with molecules
that bind to the particle surface, suggesting neither particle disas-
sembly nor steric hindrance is likely to explain NVB 71.4 blockade
activity.
DISCUSSION
The extensive burden of NoV disease on both pre- and postindus-
trialized nations warrants World Health Organization support for
development of a NoV vaccine. A new GII.4 strain has emerged
every 3 to 4 years since 2002, and the newly emergent strain, with
altered blockade epitopes, has quickly spread globally thorough
immunologically naive populations, highlighting a significant
hurdle to successful NoV vaccination regimens. Extensive work
has documented the antigenic changes in epitope A that correlate
with GII.4 strain emergence (35, 36, 42, 46), providing a possible
surveillance target for NoV monitoring. Epitope D remained
fairly static until GII.4.2012 Sydney mutations resulted in a loss of
blockade activity by human MAb NVB 97 (46). While the biolog-
ical relevance of both epitopes A and D has been confirmed with
human MAbs, the natural variation within these epitopes makes
them difficult targets for antigen-based vaccine design.
In comparison, blockade epitopes conserved among multiple
epidemiologically important strains of virus, including herd im-
munity escape mutants, provide potential targets for broadly pro-
tective vaccines, and the antibodies that recognize these epitopes
provide potential diagnostic and therapeutic reagents (50). Re-
cently, Hansman et al. (62) reported a linear GII NoV conserved
antibody epitope that is exposed transiently by proposed changes
in particle conformation. This antibody was not tested for block-
ade capacity and is unlikely to recognize the GII.4 conformation-
dependent conserved blockade epitope. The conserved GII.4
blockade epitopes recognized by human MAb NVB 71.4 and
mouse MAb GII.4.2002.G5 likely overlap but are not identical, as
NVB 71.4 can compete with GII.4.2002.G5 binding but NVB 71.4
has a higher blockade capacity and a different preferential block-
ade pattern across a panel of time-ordered GII.4 VLPs.
The concept of viral capsids as dynamic structures that can
assume different conformations is a well-established assumption
FIG 8 Predicting residues that interact with the ERK motif. (A) The ERK motif was mapped onto the crystal structure of GII.4.2004 to identify sites that may be
interacting with the ERK motif. (B) The ERK motif is highly conserved among epidemiologically important GII.4 strains, while residue 310 has evolved in the
most recent GII.4 strains with global distribution.
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in virology. Here, we map specific residues that mediate possible
conformation subsets, which may be important for manufactur-
ing NoV VLP-based vaccines. Despite identifying residue changes
that affect the blockade capacities of NVB 71.4 and GII.4.2002.G5,
we have not identified the epitope(s) that actually binds these
MAbs. For both MAbs, Kd and EC50 values were less than 2-fold
different between GII.4.2006 and GII.4.2006.ERK, and while ERK
substitutions decrease the blockade potency of the antibodies,
they do not eliminate the impact of elevated temperature on
blockade. Further, blockade of GII.4.2006 and GII.4.2006.ERK
with NVB 71.4 Fab fragments reduces the effect of ERK substitu-
tions while maintaining the effect of temperature on blockade.
These data clearly indicate that the effect of the ERK motif on MAb
blockade is not the result of loss of antibody binding to the epitope
but instead suggest that ERK regulates antibody blockade capacity
by regulating functional access to the epitope itself. Previous work
with polio virus (60) and West Nile virus (59) has shown that
temperature affects particle dynamics or “breathing” and subse-
quently antibody access to nonsurface epitopes. In both cases, at
37°C, viruses are dynamic structures reversibly exposing internal
antibody epitopes that are concealed at 25°C. Elegant studies with
flaviviruses have carefully dissected the impacts of residue
changes, time, and temperature on monoclonal antibody neutral-
ization (59, 63). Similar to observations reported here, for many
antibodies, the effect was less than 1 log unit of neutralization titer.
Given the limited impact of ERK changes on the temperature de-
pendence of blockade, the ERK domain may lie near the antibody
epitopes and influence blockade through an allosteric effect by
altering the environment surrounding the epitopes, or it may con-
formation shield the epitope from the antibody. Why GII.4 NoVs
occlude the conserved blockade epitope at room temperature but
not 37°C is unknown, but it suggests that the epitope may be
essential for infection and thus need to be exposed in the host
(37°C) but is also susceptible to degradation and thus needs to be
protected in the external environment, where infection is not a
viable option. In the absence of a feasible infection model and a
GII.4 molecular clone, it is not possible to evaluate the relation-
ship between different particle conformations (epitope accessible
versus not accessible) and infectious virus. Blockade of residue
310 mutant VLPs indicates that 310 is a conformational regulator
of access to the conserved blockade epitopes in multiple GII.4
backgrounds. Comparing blockade of GII.4.2009 (S310),
GII.4.2006 (N310), GII.4.2012 (D310), GII.4.2009.S310D, and
GII.4.2012.D310S VLPs, all in the context of the conserved ERK
motif, supports a role for residue 310 in the accessibility of the
conserved blockade epitope. Our data suggest that an aspartic acid
FIG 9 Characterization of VLPs with substitutions in residue 310 and NERK. (A) Schematic of constructs. (B and C) Particle integrity was verified by
transmission electron microscope visualization (B) and carbohydrate ligand (PGM) binding of VLPs (C). The dotted line marks the upper limit of detection in
panel C. The error bars represent 95% confidence intervals. Scale bars, 100 nm.
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at position 310 limits access to the epitope more than a serine. Our
structural analyses did not have sufficient resolution to explain the
impacts of different amino acids at position 310. Importantly,
residue 310 exchanges did not completely recapitulate the wild-
type VLP blockade temperature phenotype, suggesting that either
additional residues likely impact antibody access to the conserved
GII.4 blockade epitope or that residues within the actual epitope
vary somewhat between the two strains. Detailed crystallography
studies of antibody-bound particles are needed to answer these
fundamental questions.
Although the mechanisms of antibody blockade of VLP-carbo-
hydrate binding are not known, the correlation between the anti-
body blockade titer and protection from infection and illness has
been documented (15, 41). The location of the ERK motif on the
underside of the P domain suggests that NVB 71.4 and
GII.4.2002.G5 do not block VLP-ligand interaction by providing a
physical barrier between the VLP and the carbohydrate ligand, as
is proposed for antibodies to the surface-exposed epitopes A, D,
and E (Fig. 13) (35, 36, 47). This hypothesis is supported by
observations that NVB 71.4 binding to VLPs does not disrupt
binding of antibody to surface epitope A and that antibody Fab
fragments retain blockade activity for GII.4 VLPs. Blockade of
VLP-ligand binding is also not a function of antibody-mediated
particle disassembly or the result of the antibody binding to al-
ready disassembled particles, as MAb staining of NVB 71.4-la-
beled VLPs identified only intact particles. Instead, we hypothe-
size that NVB 71.4 and GII.4.2002.G5 likely block VLP-ligand
interaction by altering the VLP conformation, i.e., by positioning
the VLPs in an epitope-accessible conformation (with full anti-
body access to the conserved blockade epitope) that is unfavorable
for ligand binding (Fig. 14). Whether ligand binding is dependent
upon the VLP being in an epitope-restricted conformation (with
limited antibody access to the conserved blockade epitope) or the
actual transition between epitope accessible and epitope restricted
is key for ligand binding has yet to be determined. These results
mimic well-defined neutralization processes for antibodies that
recognize conformation-shielded, conserved neutralization
epitopes in a diverse group of RNA viruses, including the E protein
DI domain of West Nile virus (59, 64), the gp120 component of
the Env protein of HIV (65, 66), and the hemagglutinin stem of
influenza virus type A (66, 67). Interestingly, each of these
epitopes has residues in structural motifs that are either directly or
indirectly involved in viral entry and fusion processes, further sug-
gesting that the antibodies described here may neutralize GII.4
NoV strains by blocking the virus entry/uncoating mechanisms,
although this is speculative.
Further study of GII.4.2009 VLPs produced in an insect cell
expression system at lower temperature provides support for the
relationship between viral conformation and antibody blockade.
Blockade of Bac-GII.4.2009 by NVB 71.4 and GII.4.2005.G5 is
potent and not temperature dependent, suggesting that the native
conformation of GII.4.2009 in this system highly favors the
FIG 10 Residue 310 inversely modulates blockade potency and temperature sensitivity of the conserved GII.4 epitope. GII.4.2002.G5 (A and B) and NVB
71.4 Fab fragments and NVB 71.4 IgG (B) were assayed for the ability to block the interaction of VLPs with carbohydrate ligand at room temperature (solid
circles) and at 37°C (grey circles). Sigmoidal curves were fitted to the mean percent control binding (the percentage of VLPs bound to ligand in the
presence of antibody pretreatment compared to the number of VLPs bound in the absence of antibody pretreatment), and the mean EC50 titer for
blockade was calculated. (A and B) The fold change in potency (EC50 titer) was defined as the ratio between mutant VLPs and wild-type VLPs at room
temperature. (B) The fold change (arrow denotes increase or decrease) in temperature sensitivity was defined as the change in the ratio between the mean
EC50 at 37°C and that at room temperature for the mutant VLPs compared to the ratio at both temperatures for the wild-type VLPs. *, mean EC50 blockade
titer for mutant VLPs significantly different from the mean EC50 blockade titer for wild-type VLPs at the same temperature. The error bars represent 95%
confidence intervals. Light shading, fold increase; dark shading, fold decrease.
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“epitope-accessible” form. Conversely, GII.4.2009 VLPs made in a
mammalian expression system at 37°C require more antibody for
blockade and the blockade is temperature sensitive, indicating
that the particle assembly conditions can affect particle structure,
epitope access, and, subsequently, blockade potency for NVB 71.4
and GII.4.2002.G5. Even though the primary nucleotide se-
quences of the exogenous genes are identical in the insect cell
vector and the mammalian cell vector, multiple factors could ex-
plain the difference between the two GII.4.2009 VLPs, including
posttranslational protein processing, temperature of particle as-
sembly, and particle purification and storage conditions, all fac-
tors that could impact particle structure. Previous detailed studies
of Norwalk virus VLPs produced in insect cells indicated that the
VLPs undergo structural changes at high temperature (50°C)
and pH (8) but are stable at the pH and temperatures of the
blockade assay (68). How these studies with Norwalk virus VLPs
relate to the GII.4 VLPs studied here is unknown, as others have
shown that Norwalk and GII.4 VLPs have different pH-dependent
ligand binding characteristics (54). In agreement with the results
of Tian et al. (54), pH did not affect ligand binding of the GII.4
VLPs we tested (data not shown). Although temperature affects
both the kinetics and affinities of molecular interactions, temper-
ature alone is unlikely to explain the difference, as VLPs made by
infecting mammalian cells at 30°C with GII.4.2009 VRPs resulted
in VLPs with the same antibody blockade potency and tempera-
ture dependence as VLPs made at 37°C from the same VRP. These
data suggest that factors outside the primary nucleotide sequence,
including the host cell, may affect particle formation in subtle
ways and antibody neutralization potential in significant ways. If
the observed differences between the two GII.4.2009 VLPs studied
here is the direct result of VLP production in the baculovirus
vector system, this is key information for manufacturing the bac-
ulovirus-produced VLP NoV vaccine currently in phase I study, as
computational studies on human papillomavirus suggest that lim-
iting structural fluctuations should produce better vaccine im-
munogens (69). While the Bac-GII.4.2009 VLPs clearly allow
better antibody access to the epitopes for NVB 71.4 and
GII.4.2002.G5 than VLPs made using VRPs in the mammalian
system, it seems likely that other subsurface blockade epitopes will
be less accessible on the Bac-GII.4.2009 VLP. Detailed crystallog-
raphy studies of antibody-bound particles are needed to answer
these fundamental questions about VLP structure and how it im-
pacts cross-strain blockade antibody responses. However, all of
the crystallography studies on NoV VLPs have been done on bac-
ulovirus or other nonmammalian cell culture-derived proteins.
Given the observations presented here, the field should consider
evaluating VLPs produced in additional mammalian-based sys-
tems.
FIG 11 Antibody-bound VLPs retain structural integrity. GII.4.2009 (A
and C) and GII.4.2009.NERK (B) VLPs were immunostained with NVB
71.4 (A and B) or epitope A (C) human MAbs and visualized by negative-
stain transmission electron microscopy. The arrows indicate immunogold-
labeled VLPs.
FIG 12 Binding of NVB 71.4 does not disrupt surface epitope A topology.
Human MAbs to surface epitope A or NVB 71.4 were evaluated for the
ability to block binding of mouse MAbs to epitope A or the conserved
blockade epitope in GII.4.1997 (A) and GII.4.2006 (B) using a BOB assay.
Sigmoidal curves were fitted to the mean percent control binding (the
percentage of mouse MAb bound to VLPs in the presence of human MAb
pretreatment compared to the amount of mouse MAb bound in the ab-
sence of human MAb pretreatment), and the mean EC50 titer for blockade
of binding was calculated. Black shading, EC50  8 g/ml; grey shading,
EC50  1 g/ml.
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Antibodies to conserved GII.4 NoV blockade epitopes have
important therapeutic and vaccine potential. Human MAb NVB
71.4 could be administered prophylactically for acute or chronic
illness (70). More importantly, the antibody could be used as a
probe for antigen panning to identify the conserved blockade
epitope. The epitope could possibly then subsequently be geneti-
cally engineered to have better access within an immunizing VLP.
The supposition that locking the VLP in an epitope-accessible
conformation prevents ligand binding suggests that a drug that
could similarly lock the viral conformation could be an effective
broad-based NoV treatment, as has been described for rhinovirus
treatment with WIN compounds (71). Further, these observa-
tions open lines of inquiry into the mechanisms of human NoV
entry and uncoating, presenting fundamental biological ques-
tions that are currently unanswerable for these noncultivatable
pathogens.
FIG 13 Mapped epitopes of GII.4 noroviruses. (A) The previously described evolving antibody blockade epitopes A to E are on the surface next to the
carbohydrate binding sites (pink). (B) The NERK motif (red) is distal to the carbohydrate binding sites (pink).
FIG 14 Proposed model for regulation of antibody access to the conserved GII.4 blockade epitope(s) by the NERK motif and VLP structural conforma-
tion. GII.4 NoV VLPs produced in mammalian cells can exist in multiple conformations. Two possibilities are represented by the light- and dark-green
VLP shading. Antibody access to the conserved GII.4 blockade epitope is different in the two states. Antibody “locking” of the particle into an
epitope-accessible conformation prevents ligand binding and allows more antibody blockade activity. Further, antibody access to the conserved GII.4
blockade epitope can be regulated by the temperature and residues outside the antibody binding site. Elevated temperature or a serine at residue 310 favors
antibody access to the epitope and subsequently more blockade activity, whereas lower temperature or an aspartic acid at position 310 restricts antibody
access to the epitope, resulting in less blockade activity.
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